glp-1 npa Nexa Med Spa 1 long term GLP-1 Medications Clinic Near Me

VK0214, oral TR agonist for X-linked adrenoleukodystrophy (X-ALD) Recent Highlights: In June 2026, Viking announced that its working toward maintenance-dosing data for subcutaneous VK2735 and preparing to start Phase 3 trials of the oral tablet in Q4 2026, with the goal of becoming the first company to offer a dual GLP-1/GIP agonist in both oral and injectable form

The gliptinsalso called dipeptidyl peptidase-4 (DPP4) inhibitorsare an additional group of antidiabetic compounds with increasing worldwide clinical use since the first of them, sitagliptin, got the FDA approval in 2006 [26]

Our findings show that this type of diabetes medication shows promise in reducing alcohol consumption, potentially by targeting the brains reward centre," said study lead author Dr

Nat Rev Endocrinol (2020) 16:6156